The overall risk of infections is lower in patients undergoing non-myeloablative allogeneic stem cell transplantation (NST) than in conventional stem cell transplant recipients. We sought to evaluate conditions associated with increased risk of infections after NST. In 81 patients, 187 infection episodes were noted; chronic lymphocytic leukemia (138 episodes/100 person-years) and recipients of matched unrelated donor graft (128 episodes/100 person-years) had higher risk of infection. Only half of the cytomegalovirus (CMV) infections occurred 31-100 days after transplantation. Most patients with CMV infection were non-neutropenic (100%), had lymphoma (76%), were younger (o55 years; 72%) and had received matched related donor (MRD) graft (72%). However, graft-versus-host disease (GVHD) was present in only 15% of these patients. Seven (78%) of nine invasive fungal infections (IFI) were diagnosed 4100 days after NST and were associated with high mortality (78%). Most patients with IFI were also not neutropenic (100%), had received MRD graft (100%), had lymphoma (78%) and were given systemic steroids (78%); unlike CMV infection, 67% of these patients also had GVHD. On the basis of our results, we propose that NST recipients with lymphoma treated with high-dose corticosteroids for GVHD be considered for antifungal prophylaxis or preemptive antifungal therapy.
Introduction
Patients who are not eligible for severe immunosuppressive myeloablative preparatory therapy before allogeneic stem cell transplantation (SCT) can be considered for reducedintensity non-myeloablative allogeneic SCT (NST). 1, 2 The gradual replacement of the immune system with donor stem cells promotes alloreactive T-lymphocytes and natural killer cells, which mitigate host tumor cells and lead to durable cancer remission. [3] [4] [5] Thus, NST provides an effective alternative therapy for patients with relapsed or recurrent lymphoid and myeloproliferative diseases. [6] [7] [8] Patients older than 55 years are at high risk for serious complications after conventional SCT; NST is an effective alternative. 7 NST also provides an important treatment option for high-risk young patients, in whom conventional myeloablative conditioning may lead to serious adverse events. 8 Early infections are less common in patients undergoing low-intensity immunosuppressive preparatory conditioning for NST than in those undergoing conventional allogeneic SCT. [6] [7] [8] [9] However, on account of the slow recovery of the pathogen-specific T-cell response after NST, patients may remain susceptible to opportunistic infections for an extended period after transplantation. 9 Infections emerging later than day 100 after transplantation are often seen in recipients of stem cells from unrelated donors, increasing the risk of graft-versus-host disease (GVHD) and further delaying adaptive cellular and humoral immune recovery. Patients older than 55 years also have slower immune recovery after transplantation, independent of GVHD and their susceptibility to opportunistic infections; therefore, they remain at high risk for infections long after NST. [9] [10] [11] [12] In this study, we evaluated infections in patients undergoing NST for lymphoid malignancies at our National Cancer Institute designated a comprehensive cancer center.
Patients and methods

Study design
We retrospectively analyzed all consecutive episodes of infection in NST recipients with lymphoid malignancies at The University of Texas MD Anderson Cancer Center (Houston, TX, USA) between November 1999 and March 2004. The study was undertaken after obtaining approval from the institutional review board. The data were collected from electronic medical records and patients were identified using the Department of Stem Cell Transplantation database. Only follow-up data up to these end points were collected and analyzed: (1) cancer relapse, (2) death, (3) subsequent SCT, (4) diagnosis of another primary cancer or (5) antineoplastic chemotherapy. Patients with relapsed cancer were also followed to evaluate the effects of donor lymphocyte infusions (DLIs) and the risk of infection.
Preparative regimens
The NST preparative regimen had included 30 mg/m 2 per day of fludarabine and 750 mg/m 2 per day of cyclophosphamide on days À5, À4 and À3 and 375 mg/m 2 of rituximab followed by 1000 mg/m 2 on days À6, þ 1 and þ 8.
Prophylaxis and surveillance GVHD prophylaxis consisted of 0.015 mg/kg per day of tacrolimus from day À2 (dose adjusted to maintain a trough level of 5-15 ng/ml) and 5 mg/m 2 of methotrexate on days 1, 3 and 6. In patients undergoing matched unrelated donor (MUD) transplants, methotrexate was also given on day 11. Tacrolimus was maintained for 6 months in patients who had received MUD stem cells; the tacrolimus dose was then tapered. Acute and chronic GVHD was graded using standard criteria. 11, 12 Infection surveillance included twice-weekly testing for cytomegalovirus (CMV) antigenemia during transplant hospitalization and weekly testing after discharge from the hospital for the first 100 days after transplantation. As serum galactomannan assays are available at our institution, these assays had been performed as often as had the CMV antigenemia tests. Cultures for other microbes had been performed when clinically indicated.
CMV prophylaxis had included 900 mg of oral valgancyclovir twice daily on days À7 to À2. On day À1, valgancyclovir was replaced with 60 mg/kg per day of i.v. foscarnet. Foscarnet was replaced with oral valgancyclovir after neutrophil engraftment. Trimethoprim-sulfamethoxazole (double-strength tablet twice a day biweekly) or, in case of allergy to sulfonamides, pentamidine (4 mg/kg, i.v. given every 4 weeks) had been used to prevent Pneumocystis carinii infection. Seventy patients (86%) had received trimethoprim-sulfamethoxazole. Other antimicrobial prophylaxis agents included levofloxacin in 48 patients (59%) and fluconazole in 54 patients (66%).
Microbiologic evaluation
All microbiologic evaluations had been performed in MD Anderson Cancer Center's Microbiology Laboratory using standard methods. Drug-susceptibility testing had been performed according to the National Committee on Clinical Laboratory Standards guidelines where applicable.
Definitions
Patients 18 years or older were considered adults. Early infections were defined as those occurring within 100 days after NST, and late infections were defined as those occurring 4100 days after transplantation. 13 All positive blood cultures for a single organism during hospitalization were considered to represent a single episode of infection. Two or more positive blood cultures with similar antibiotic sensitivity were needed to diagnose coagulasenegative staphylococcus bacteremia in patients with signs and symptoms of infection.
14 A polymicrobial infection episode was defined as 41 disease-associated organism isolated from the blood or bronchial cultures in samples obtained within 72 h of each other. 15 An infection episode was considered to be microbiologically documented if a disease-causing microorganism was identified from a sterile body site or from a non-sterile site that was considered to be infected on physical examination. Infections were clinically documented if fever or other signs and symptoms of infection were present, along with radiographic features consistent with pulmonary, sinus, brain, bone, skin and soft tissue infection, but no pathogen was isolated. A fever of unknown origin was defined as the presence of persistent fever (X72 h) without clinical, radiologic or microbiologic evidence of infection or other obvious causes. Invasive fungal infections (IFI) were defined using standard guidelines. 16 CMV and other viral infections were also defined according to standard guidelines. 17 A progressive, complicated or serious infection was defined as sepsis syndrome or septic shock-related multiorgan failure, including adult respiratory distress syndrome. 18 Infectionrelated death was defined as death within 2 weeks of the last positive culture among microbiologically documented infections in the absence of known non-infectious causes of death. Similarly, for patients with clinical and/or radiographic diagnosis of infection, infection-associated deaths were defined according to established guidelines. 10 
Statistical analysis
We calculated frequencies and percentages to summarize patient, infection and transplantation characteristics. Categorical data were analyzed using the w 2 test or Fisher's exact test, and discrete variables were analyzed using a t-test; a two-sided Po0.05 was considered statistically significant. A backward logistic regression analysis model was used for factors predictive of infection in a multivariate analysis. A Kaplan-Meier analysis was also undertaken to evaluate predictors of survival after NST. Matched related donors (MRDs) and MUDs were compared, as were lymphoma and chronic lymphocytic leukemia (CLL) patients. The model intensity was fitted to consider recurring events. Statistical analyses were performed using SPSS statistical software version 12.0 (SPSS, Inc., Chicago, IL, USA) and SAS software version 9.1 (SAS Institute, Cary, NC, USA).
Results
Patients and transplantation
Eighty-one patients were included in this study. Their characteristics are shown in Table 1 . Median age was 53±8 years and 64% were men. Most patients had non-Hodgkin's lymphoma (NHL, 73%). At the time of transplantation, in 74% of these patients, the disease was in complete or partial remission, and in 70% the disease was a prior cancer relapse. Most patients had received peripheral blood stem cells from human leukocyte antigenidentical (85%) and -related donors (88%). The median time to myeloid engraftment was 11 days; 30% of patients experienced acute or chronic GVHD.
Infections occurred in 86% of NST recipients; there were no significant differences between these patients and those who did not experience infections (Table 2) . Patients who had undergone NST from unrelated donors had received significantly more prior courses of chemotherapy (Po0.004) and experienced acute GVHD (Po0.001) more often and earlier (Po0.0001) than had patients who had undergone NST from related donors (Table 3) . No CLL patients had undergone prior SCT (Po0.004); they experienced GVHD earlier (54 vs 184 days in NHL; Po0.02) and cancer relapse or graft failure more frequently (Po0.003) than did NHL patients (Table 3) .
Infection episodes
One hundred eighty-seven episodes of infection occurred during a median of 48 weeks of post transplantation follow-up in 70 patients. The highest infection frequency was noted in CLL patients (138 episodes/100 person-years) and those who had undergone MUD SCT (128 episodes/ 100 person-years) ( Table 4 ). Most infections had been microbiologically diagnosed in CLL patients (82 episodes/ 100 person-years) and those who had undergone MRD SCT (80 episodes/100 person-years) compared with those who had undergone unrelated donor NST (38 episodes/ 100 person-years) ( Table 4 ). The total time at risk for infection was also higher in young patients (age o55 years), NHL patients and matched related NST recipients (Table 4) . Table 5 shows infection episodes in relation to the interval after transplantation. In 76 (41%) of 187 episodes, infections were diagnosed on the basis of clinical findings; fever of unknown origin (n ¼ 22 (12%)), pneumonia (n ¼ 17 (9%)) and sinusitis (n ¼ 10 (5%)) were the main presentations. Infections were microbiologically documented in 111 episodes (59%) and 30% of these were viral infections. CMV viremia or end-organ disease accounted for 44% of all viral infections. Half of the CMV infections occurred between 31 and 100 days after transplantation. Most patients with CMV were non-neutropenic (100%), had lymphoma (76%), were aged o55 years (72%) and had undergone transplantation from MRDs (72%); GVHD was present in only 15% of these patients at the time the infection was diagnosed. Other viral infections included respiratory syncytial virus (n ¼ 9 (8%)), parainfluenza, influenza and varicella zoster viruses (n ¼ 6 each (5%)). Interestingly, only three episodes (two patients) of BK virus cystitis were noted, with no evidence of GVHD a mean of 39 days after transplantation.
Seven (78%) of nine IFI were diagnosed in the late (4100 days) transplantation period; seven patients (78%) died of invasive fungal disease. Absence of neutropenia (100%), MRD grafts (100%), NHL (78%), prior steroid use (78%) and GVHD (67%) were common in patients with fungal infections.
In 44 of 111 microbiologically diagnosed episodes (40%), bacteria were considered the causative agents, including 
17 (24) 3 (27) 40.9
Abbreviations: CLL ¼ chronic lymphocytic leukemia; CMV ¼ cytomegalovirus; GVHD ¼ graft-versus-host disease; NHL ¼ non-Hodgkin's lymphoma; SCT ¼ stem cell transplantation. Infections in non-myeloablative stem cell transplantation patients A Safdar et al (5%)). In 24 (22%) episodes of pneumonia, 3 of 6 Grampositive bacterial infections were due to Streptococcus pneumoniae and the other 3 were due to Pseudomonas species; 9 episodes of possible (n ¼ 2), probable (n ¼ 5) or proven (n ¼ 2) invasive aspergillosis and a single episode of pneumocystis pneumonia were observed. Clinical infection syndromes were more common in related donor graft recipients than in unrelated donor stem cell recipients (27 vs 2%; Po0.001) ( Table 6) .
Twenty patients (25%) experienced a cancer recurrence a mean of 219±235 days after transplantation; 11 of these patients received a total of 21 DLIs. Five infection episodes in three patients occurred a mean of 34 ± 78 days after DLI, including two episodes of CMV infection; one of these patients had CMV, respiratory syncytial virus and adenoviral pneumonitis. No fungal infections were noted after DLI.
Multivariate analysis
A logistic regression analysis showed that a history of SCT (odds ratio (OR): 0.19, 95% confidence interval (23) 26 (23) 18 (25) 25 (20) 19 (30) 39 (25) 5 (17) Gram positive 26 (14) 18 (16) 8 (11) 15 (12) 11 (17) 23 ( Outcome Lymphoma patients undergoing NST had longer overall survival durations than did CLL patients (Figure 1 ). However, no difference was found in patients receiving matched related or MUD SCT (Kaplan-Meier results not shown). Infection-related deaths are shown in Table 7 . One patient died of S. pneumonia sepsis during treatment for limited chronic GVHD involving the liver and skin.
Discussion
The overall infection rate after NST was higher in patients with CLL compared with lymphoma patients. Similarly, recipients of unrelated donor stem cells had increased frequency of infections compared with patients given related donor grafts. Interestingly, IFI and CMV reactivations were more common in lymphoma patients. Presence of GVHD was more frequently associated with invasive fungal disease, whereas CMV viremia or end-organ disease was mostly seen in the early or late post-engraftment period, in younger lymphoma patients who did not have GVHD. The frequencies of early and late infection episodes were similar and most febrile episodes of unknown etiology (73%) occurred within 30 days after transplantation. It is noted that 80% of microbiologically diagnosed infection episodes were identified 30 days after NST. In NST, the stem cell graft induces an immune-mediated antitumor graft-versus-tumor/leukemia effect without the need for ablation of recipient immunity, [19] [20] [21] which can be further augmented by DLIs. 22, 23 This strategy has been used to promote the antineoplastic effect in patients with residual disease or disease relapse after transplantation. DLI response is high in patients with mixed chimerism because T-cell-dependent lymphohematopoietic GVHD is the basis for DLI-mediated antitumor activity, which requires an intact cascade of antigen presentation. 24, 25 In patients undergoing DLIs, the risk of infection is offset by GVHD, which follows DLI and may enhance immune suppression. 26 In our study, few infections were observed even in patients who received multiple DLIs. CMV viremia or pneumonitis in our DLI recipients may suggest that CMV reactivation may occur after DLIs and that antiviral prophylaxis or pre-emptive therapy in high-risk patients may need to be evaluated further.
Patients undergoing NST for lymphoma with indolent disease have durable disease-free survival compared with patients with high-grade malignancy. 19, 20, 27 Our findings were similar: lymphoma patients whose pre-transplant disease was stable or in remission had a higher probability of long-term survival compared with CLL patients who underwent NST under the same treatment protocol (Figure 1 ). Patients with CLL had a high frequency of infection complications (Table 4 ). This may be because of prolonged B-cell dysfunction and hypogammaglobulinemia that may not recover even after successful transplantation. Interestingly, most bacterial infections in CLL patients were caused by Gram-positive bacteria including invasive pneumococcal disease reflecting suboptimum opsonizing immunoglobulin. Infections in non-myeloablative stem cell transplantation patients A Safdar et al
The duration of neutropenia is brief after NST, most infections occurring during the post-engraftment period. 30, 31 Bacterial infections are common during this period, especially in older patients and recipients of MRD grafts. 30, 31 GVHD is less common after NST (12-14%) than after conventional transplantation (36-40%). 21 The low rate of GVHD in NST recipients is an independent factor that favorably influences the risk of infection and non-cancer relapse-related deaths. Similarly, in our study, the infectionrelated death rate was low (15%), even though clinically significant GVHD occurred in 20% of old patients and 25% in patients o55 years of age. It was not unexpected that only one patient who died of pneumococcal sepsis was undergoing treatment for chronic GVHD (Table 7) .
In patients with hematologic malignancies who undergo partially matched NST, the risk of CMV reactivation and end-organ disease is high. 32 This is partly attributed to the delayed recovery of the adaptive T-cell immune response, which may take longer than 6 months to regenerate. 32 In older patients and those with underlying lymphoma and serologic evidence of prior CMV infection, post transplantation CMV reactivation is a concern. 31 In this study, CMV disease constituted only 23% of all microbiologically documented infections, and half of these were noted during the early post-engraftment period (31-100 days after transplantation). Other reports have shown higher frequencies of CMV antigenemia (29%) after NST, although the rate of CMV end-organ disease had been low and time to CMV reactivation was 54 days, 33 which is in agreement with our finding. In reports that showed that post transplantation lymphocyte recovery was similar among recipients of NST and conventional allogeneic SCT, the rates of CMV antigenemia were also comparable between the two groups (36 vs 39%, respectively). 34 In patients undergoing severe T-cell-depleted NST, more than half of the CMV-seropositive patients who had received stem cell grafts from CMV-positive donors had evidence of CMV reactivation, which was mitigated with antiviral prophylaxis. 35 Others have shown higher CMV-specific T-cell recovery on days 30 and 90, which was correlated with lower rates of CMV reactivation in SCT recipients who had undergone reduced-intensity conditioning. 30 Prolonged deficiency of antigen-specific T cells after T-cell-depleted transplantation has emerged as an important risk factor for treatment-refractory opportunistic infections, including CMV disease. [36] [37] [38] We did not observe EBV lymphoproliferative disease, and viral respiratory tract infections were also uncommon (5%) compared with 12% seen at other institutions. 39, 40 IFI are less common (2%) after NST than after conventional transplants (12%). 38 In our study, the incidence of IFI was 9% and comparable to that described by others (8%). 39 However, the severity of these infections and infection-attributable deaths (78%) was considerably higher in these patients despite less severe immune dysfunction compared with recipients of conventional myeloablative hematopoietic SCT. 41, 42 Other centers have also reported high rates of IFIs (32%), with higher rates of proven (23%) fungal disease, after NST. 39 Clinically significant GVHD, steroid therapy, recurrent neutropenia and relapsed malignancy after NST are recognized risk factors for IFIs. 39 The 80% mortality rate noted in this report corresponds to the higher number of deaths owing to IFIs in our patients (Table 7) . 39 Patients with invasive aspergillosis have a 4two-fold higher risk of death, and the presence of intestinal GVHD increases this risk. 42 A high leukemia burden at the time of transplantation also predicts poor outcome. 19, 22, 43 Measures to prevent opportunistic infections in at-risk population should be included in long-term management plans for NST recipients. 44 Patients with increased risk of fungal disease included (1) patients receiving highdose systemic corticosteroids usually for 42 weeks 39 and (2) patients with severe (grade III-IV) GVHD, whereas younger CMV-seropositive NST recipients with lymphoma, who received stem cell graft from a CMV-positive donor even in the absence of GVHD or corticosteroid use, need monitoring for viral reactivation during the postengraftment period.
